Drugs & TargetsFree FDA gives accelerated approval to Modeyso as the first and only treatment for recurrent H3 K27M-mutant diffuse midline glioma August 08, 2025Vol.51 No.31
FreeIn the Archives Rick and Mary Pazdur on facing “the other side of the stethoscope”A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology July 11, 2025Vol.51 No.27By Katie Goldberg
FreeGuest Editorial As cancer scientists, we must change how we engage with the public on the impact of NIH cutsWhat the scientific method obscures July 03, 2025Vol.51 No.26By George J. Weiner and Elizabeth M. Jaffee
Free In weekly vigils, current and former NIH staff grieve the impact of Trump cutsThe Saturday gatherings at NIH’s Metro station are part graveside service, part street theater July 03, 2025Vol.51 No.26By Claire Marie Porter
FreeIn the Archives Since 1991, the Women’s Health Initiative has saved lives, cut costs, and fostered team science July 03, 2025Vol.51 No.26
FreeGuest Editorial Building cancer care resilience through international observerships: Lessons from Ukraine June 27, 2025Vol.51 No.25By Nataliya Kovalchuk, Andriy Beznosenko, Vitaliy Y. Poylin, Rostyslav Semikov, Arman Kacharian, Douglas Davis, Nataliya Uboha, Natalka Suchowerska, Viktor Iakovenko, Jacqueline Hart, Mark Poznansky, Darya Kizub and Nelya Melnitchouk
EditorialFree The Cancer Letter receives nine journalism, design awards June 13, 2025Vol.51 No.23By Katie Goldberg
Free Young women are now diagnosed with cancer at twice the rate of young menThe face of cancer is changing at a time when research is plagued by existential threats June 06, 2025Vol.51 No.22By Claire Marie Porter
FreeObituary Harmon Eyre, former ACS chief medical and scientific officer, dies at 84 June 06, 2025Vol.51 No.22By Otis W. Brawley
FreeIn the Archives Melvin J. Silverstein reflects on 25 years of controversy surrounding DCIS and radiation June 06, 2025Vol.51 No.22
